Curaleaf International Acquires Can4Med, Expanding Presence in Poland's Growing Medical Cannabis Market
Acquiring Company
Curaleaf International
Acquired Company
Can4Med
London
PolandBiotechnology ResearchPharmaceutical ManufacturingDescription
Curaleaf International, Europe's largest vertically integrated cannabis company and part of Curaleaf Holdings, has acquired Can4Med, a prominent pharmaceutical wholesaler specializing in cannabinoid medications in Poland. This strategic move allows Curaleaf to enhance patient access to high-quality medical cannabis products and gain a strong foothold in Poland's dynamic market.
Quick answer
Curaleaf International is acquiring Can4Med, announced February 6, 2024. Curaleaf International is based in London, England, United Kingdom.
- How much did Curaleaf International pay for Can4Med?
- The deal value was not disclosed.
- What does Curaleaf International do?
- Curaleaf International is unlocking the transformative power of medical cannabis by empowering patients and healthcare professionals with knowledge and access to cannabis-based therapies.
- Where are Curaleaf International and Can4Med based?
- Curaleaf International is based in London, England, United Kingdom. Can4Med is based in Poland.
Source: Fundz verified event record.
Other recent acquisitions in Biotechnology Research and Pharmaceutical Manufacturing
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Merck Animal Health to Acquire Elanco’s Aqua Business (February 5, 2024)
- ClinChoice Acquires CSI, Expanding its Global Footprint into Southeast Asia (January 12, 2024)
- Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc. (February 26, 2024)
- Spectrum Science Acquires Continuum Clinical, Amplifying Patient Recruitment Capabilities (February 8, 2024)
- Aurora Cannabis Acquires MedReleaf Australia (February 8, 2024)
- Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems (February 6, 2024)
Who to call at Curaleaf International, and when
When Curaleaf International changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Curaleaf International raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Curaleaf International, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Curaleaf International. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Curaleaf International makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Can4Med?
Can4Med was acquired by Curaleaf International, based in London. The deal was reported on February 6, 2024. Curaleaf International is unlocking the transformative power of medical cannabis by empowering patients and healthcare professionals with knowledge and access to cannabis-based therapies. Curaleaf International is privately held and operates in Biotechnology Research.
When did Curaleaf International acquire Can4Med?
Curaleaf International's acquisition of Can4Med was reported on February 6, 2024. Curaleaf International, Europe's largest vertically integrated cannabis company and part of Curaleaf Holdings, has acquired Can4Med, a prominent pharmaceutical wholesaler specializing in cannabinoid medications in Poland. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Can4Med do?
It is privately held, operating in Pharmaceutical Manufacturing, and is based in Poland.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.